Basket cover image
15 handpicked stocks

The Great Energy Realignment

Recent US tariff threats against buyers of Russian oil and a major new energy deal with the EU are redirecting global energy demand. This creates a prime opportunity for U.S. energy producers and exporters poised to meet Europe's growing needs.

stock
stock
stock
stock
stock
stock
stock
stock
stock
stock

+5

Author avatar

Han Tan | Market Analyst

Updated 3 days ago | Published at juillet 31

Top Picks from This Group

Here are a few of the assets in this group. Create an account to unlock the full list.

XOM

Exxon Mobil Corp.

XOM

Current price

$107.42

EOG

EOG Resources, Inc.

EOG

Current price

$117.32

EPD

Enterprise Products Partners L.P.

EPD

Current price

$31.41

About This Group of Stocks

1

Our Expert Thinking

Geopolitical pressures and new trade agreements are creating a massive shift in global energy flows. As Europe moves away from Russian oil due to US tariff threats, American energy producers are perfectly positioned to fill this gap. The new US-EU energy deal worth $750 billion represents a structural change that could benefit US companies for years to come.

2

What You Need to Know

This group focuses on the entire US energy export supply chain - from upstream oil and gas producers to midstream pipeline operators and LNG export facilities. These companies are positioned to serve a large, secure European market with sustained high demand. The theme captures both immediate opportunities and long-term structural advantages.

3

Why These Stocks

These stocks were handpicked by professional analysts based on their strategic positioning in the trans-Atlantic energy bridge. Each company plays a crucial role in either producing or transporting American energy to European markets, making them prime beneficiaries of this historic realignment in global energy trade.

12 Month Growth Potential

Use the growth calculator to see how much investing in these assets could return over one year.

If you invested across these assets:

in 12 months it could be worth:

$1,000.00

+63.18%

Group Performance Snapshot

63.18%

Average 12 Month Profit

On average, analysts expect assets in this group to grow 63.18% over the next year.

14 of 15

Stocks Rated Buy by Analysts

14 of 15 assets in this group are rated Buy by professional analysts.

Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.

Why You'll Want to Watch These Stocks

🌊

Historic Energy Shift

We're witnessing a once-in-a-generation realignment of global energy flows. As Europe pivots away from Russian oil, American producers are stepping in to fill a massive $750 billion opportunity.

🚀

Secured European Demand

Unlike volatile spot markets, this represents long-term, contracted demand from a stable, wealthy trading partner. These companies now have visibility into sustained revenue growth for years ahead.

Infrastructure Advantage

The US already has the production capacity and export infrastructure in place. These companies don't need to build from scratch - they're ready to capitalise on increased demand immediately.

Why Invest with Nemo Money?

Nemo Logo Fade
🆓

Zero Commission

Trade stocks, ETFs, and more with zero commission. Keep more of your returns.

🔒

Trusted & Regulated

Part of Exinity Group 2015, serving over a million customers globally.

💰

6% Interest on Cash

Earn 6% AER on uninvested cash with daily interest payments.

Discover More Opportunities

The New Cost of Compliance: Investing in HR Tech

The New Cost of Compliance: Investing in HR Tech

Australian airline Qantas received a historic $58 million fine for unlawfully dismissing workers, setting a new precedent for corporate accountability in labor practices. This ruling creates an investment opportunity in companies that provide the essential HR, legal, and compliance technologies businesses now need to navigate stricter labor law enforcement.

View stocks
GLP-1s Target Liver Disease

GLP-1s Target Liver Disease

The FDA's approval of Wegovy for a serious liver disease has boosted Novo Nordisk's market position and highlighted a major new application for GLP-1 drugs. This development creates an investment opportunity in companies focused on innovative treatments for metabolic and liver-related conditions.

View stocks
Pharma's Digital Prescription

Pharma's Digital Prescription

Novo Nordisk is partnering with GoodRx to offer its popular drug Ozempic at a reduced price, boosting GoodRx's stock. This collaboration highlights a growing trend of pharmaceutical companies leveraging digital health platforms to improve drug affordability and expand market reach.

View stocks
View All Stock Groups

Frequently Asked Questions

Everything you need to know about the product and billing.